Cytomegalovirus (CMV) CD8 t-cell immune competence, quantitative assessment by Flow Cytometry

Alphabetical Test listing

Cytomegalovirus (CMV) CD8 t-cell immune competence, quantitative assessment by Flow Cytometry-994

  
Cytomegalovirus (CMV) CD8 t-cell immune competence, quantitative assessment by Flow Cytometry
  
994
  
LAB994
  
MSO
  
CMV (Cytomegalovirus)
Cytomegalic inclusion disease (CMID)
Cytomegalovirus (CMV)
CMID (Cytomegalic Inclusion Disease)
  
  • Assessing cytomegalovirus (CMV)-specific immune competence in allo-hematopoietic stem cell transplantation patients who are at risk for developing late CMV disease (beyond day 100 after transplant)
  • Assessing CMV-specific immune competence in solid organ transplant patients who are at high risk for CMV reactivation post-transplant
  • Monitoring immune competence in patients post-primary CMV infection after transplant who are at risk for CMV reactivation after the cessation of antiviral prophylaxis
  • Identifying individuals who are likely to be protected from post-transplant CMV infection and those who are at higher risk of CMV reactivation
  • The global CD8 T cell immune competence assay is useful for determining over immunosuppression within the CD8 T cell compartment, when used on transplant recipients and patients with autoimmune disorders receiving therapy with immunosuppressant agents
  
Sodium heparin (Na hep) whole blood
  
  
20 mL
  
10 mL
  

Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting

  

Dk green Sodium heparin (Na hep), no gel

  

Ambient - 48 hours

  • Specimens should be collected Mo - Th only.
  • It is recommended that specimens arrive at Mayo within 24 hours of draw.
  
  • Gross hemolysis
  • Groos lipemia
  
Mayo Clinic Laboratories (CMVC8): R-NX
  
Mo - Fr
  
3 - 6 days
  

Flow Cytometry

  

See report

  
86356 x6
86359
86352
  
Yes
  
  
06/13/2019
  
01/08/2024
  
01/08/2024